Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone

BACKGROUND: Opicapone, a recently introduced catechol‐o‐methyl transferase (COMT) inhibitor has the advantage of being administered once daily, and has pharmacokinetic data to indicate it offers a greater degree of COMT inhibition than entacapone. Although trial data indicate it is non‐inferior to e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mov Disord Clin Pract
Main Authors: Vokurka, Petr, Barron, Andrew, Sumaria, Sheetal, Stockford, Lindsey, Jarman, Paul, Bhatia, Kailash, Farmer, Simon, Saifee, Tabish, Warner, Tom, Weil, Rimona, Gandhi, Sonia, Limousin, Patricia, Korlipara, Prasad, Foltynie, Tom
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604656/
https://ncbi.nlm.nih.gov/pubmed/33163567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.13094
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados